A Retrospective Real-World Study Based on RATIONALE-307

Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07478809

Enrollment

109

Registered

2026-03-18

Start date

2026-02-28

Completion date

2027-12-31

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Brief summary

The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.

Interventions

OTHERNo intervention

No intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion

Exclusion criteria

* Patients who had a documented death before study completion in the RATIONALE-307 trial

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS)	Defined as the time from the date of randomization in the RATIONALE-307 trial to the date of death from any cause occurring on or before December 31, 2025.

Countries

China

Contacts

CONTACTZhijie Wang, MD

jie_969@163.com+86 13466323860

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026